Qnovia, Inc., a pharmaceutical company who recently announced the clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for the RespiRx™ Nicotine ...

Nicotine inhalation system 10mg (4mg delivered ... then reduce gradually over 12 more weeks. Inhaler: peak plasma concentrations of 49ng/mL reached within 15 minutes. Nasal spray: maximum ...

The funding will primarily be allocated toward the submission of an application to British regulators to allow for the ...

Qnovia has received clearance from the US Food and Drug Administration (FDA) to start a clinical trial for its RespiRX ...

Background: Even with effective smoking cessation medications, many smokers are unable to abruptly stop using tobacco. This finding has increased interest in smoking reduction as an interim step ...

In conclusion, NRT (nicotine gum or inhaler) doubled the quit rate compared to placebo and was safe. Active NRT achieved sustained abstinence rates of 20.1% at 4 months and 18.7% at 12 months ...